ORTX Stock Overview Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Orchard Therapeutics plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Orchard Therapeutics Historical stock prices Current Share Price US$16.70 52 Week High US$16.72 52 Week Low US$4.24 Beta 0.55 1 Month Change 1.71% 3 Month Change 4.57% 1 Year Change 188.88% 3 Year Change -70.28% 5 Year Change -86.41% Change since IPO -88.07%
Recent News & Updates
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel) Mar 20
Orchard Therapeutics Files Form 15 Feb 06
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome Feb 05
Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others. Jan 26 Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR Jan 19 See more updates
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel) Mar 20
Orchard Therapeutics Files Form 15 Feb 06
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome Feb 05
Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others. Jan 26 Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR Jan 19
New major risk - Financial position Dec 17
Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy Dec 12
Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH Dec 01
Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023 Nov 17
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 15
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023 Oct 27
Price target decreased by 25% to US$16.00 Oct 12 Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million. Oct 06
New major risk - Share price stability Oct 05 Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review Sep 20
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023 Sep 01
Consensus estimates of losses per share improve by 55% Aug 10
New major risk - Shareholder dilution Aug 06
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Consensus EPS estimates fall by 30% Jul 02
Consensus EPS estimates upgraded to US$1.61 loss Jun 14
Consensus EPS estimates upgraded to US$1.81 loss May 24
Consensus revenue estimates decrease by 18%, EPS upgraded May 22
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT May 20
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price May 09
Price target decreased by 28% to US$21.60 Mar 15
Price target decreased by 8.7% to US$27.40 Mar 13
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment? Mar 10
Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations Jan 18
Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH Jan 06
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA Dec 13
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel) Dec 02
Price target decreased to US$3.67 Nov 18
Insufficient new directors Nov 16
Orchard Therapeutics: Gene Therapy For Rare Child Disease Aug 19
Consensus forecasts updated Aug 11
Price target decreased to US$3.67 Aug 10
Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M Aug 04
Price target decreased to US$3.67 May 19
Price target decreased to US$4.00 Apr 27
Insufficient new directors Apr 27
Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq Apr 09
Consensus revenue estimates increase by 37% Mar 31
Price target decreased to US$8.64 Mar 30
Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD Jan 22
Orchard Therapeutics: Shadow Of Former Glory Jan 20
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones Jan 12
Consensus forecasts updated Jan 12
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020) Nov 06
Price target decreased to US$10.31 Nov 06
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event Sep 15
Consensus forecasts updated Aug 19
Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles Aug 16
Consensus forecasts updated Aug 11
Price target decreased to US$11.70 Aug 05
Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V. Jul 02
Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs Jun 30
Price target decreased to US$13.00 Jun 30
Consensus forecasts updated Jun 30
Independent Non-Executive Director Jon Ellis has left the company Jun 22
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry? Jun 14
Consensus forecasts updated May 20
Orchard Therapeutics Announces Data Published in the New England Journal of Medicine Evaluating the Safety and Efficacy of Investigational Gene Therapy Products, Including OTL-101 May 12
Consensus revenue estimates fall to US$11.5m Mar 18 Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019) Mar 04
Revenue behind estimates Mar 04
Orchard Therapeutics plc Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome Feb 10
Orchard Therapeutics plc announced that it expects to receive $149.999996 million in funding from RA Capital Management, L.P., Avidity Partners Management LP, Casdin Capital, LLC, Farallon Capital Management, L.L.C., Citadel Enterprise Americas LLC and other investors Feb 06
New 90-day high: US$7.39 Feb 06
What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)? Feb 03
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer Jan 31
Orchard Therapeutics appoints Braden Parker as chief commercial officer Jan 29
Orchard Therapeutics Secures Partnerships to Broaden Access to Libmeldy for Eligible Patients in Middle East & Turkey Jan 20
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD) Jan 15
Orchard Therapeutics' OTL-200 wins FDA's RMAT status Jan 14
Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022 Jan 12
Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount? Jan 08
New 90-day high: US$6.50 Jan 07
Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy Dec 23
Orchard Therapeutics' MLD gene therapy wins European nod Dec 21
Our View On Orchard Therapeutics Dec 17
Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year Dec 11
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Dec 10
Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study Dec 08
Orchard Therapeutics (ORTX) Investor Presentation - Slideshow Nov 22
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD) Nov 20 Shareholder Returns ORTX US Biotechs US Market 7D 0.9% -3.8% -2.7% 1Y 188.9% -2.6% 23.4%
See full shareholder returns
Return vs Market: ORTX exceeded the US Market which returned 19% over the past year.
Price Volatility Is ORTX's price volatile compared to industry and market? ORTX volatility ORTX Average Weekly Movement 0.6% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: ORTX has not had significant price volatility in the past 3 months.
Volatility Over Time: ORTX's weekly volatility has decreased from 16% to 1% over the past year.
About the Company Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.
Show more Orchard Therapeutics plc Fundamentals Summary How do Orchard Therapeutics's earnings and revenue compare to its market cap? ORTX fundamental statistics Market cap US$380.12m Earnings (TTM ) -US$72.92m Revenue (TTM ) US$21.84m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ORTX income statement (TTM ) Revenue US$21.84m Cost of Revenue US$79.52m Gross Profit -US$57.68m Other Expenses US$15.24m Earnings -US$72.92m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -3.20 Gross Margin -264.11% Net Profit Margin -333.90% Debt/Equity Ratio 31.9%
How did ORTX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/01/24 15:20 End of Day Share Price 2024/01/24 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Orchard Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Charles Duncan Cantor Fitzgerald & Co. Emma Nealon Cantor Fitzgerald & Co. Graig Suvannavejh Goldman Sachs
Show 7 more analysts 
